To quantify 5-year downstream outcomes following a PSA screening level exceeding 4.0 ng/mL in older men, Walter et al studied 295 645 men 65 years or older who underwent PSA screening in the Veterans Affairs health care system in 2003 and were followed up for 5 years using national Veterans Affairs and Medicare data. See the editorial by Katz.
A comparison of Michigan and non-Michigan hospitals was conducted by Saint et al to identify practices currently used to prevent catheter-associated urinary tract infection and to compare the use of standardized infection ratios for a national sample of US hospitals. See the Invited Commentary by Pottinger and the Original Investigation by
Krein et al examine the experiences of hospitals participating in a Michigan program to reduce unnecessary use of urinary catheters (Bladder Bundle) and identify ways to enhance efforts to prevent catheter-associated urinary tract infection. An invited commentary by Pottinger follows.
Deaño et al determine the accuracy of pulmonary hypertension (PH) diagnoses in patients referred to PH centers and the frequency of pulmonary arterial hypertension–specific medication use despite an uncertain or incorrect diagnosis. Redberg provides an Editor’s Note.
Pitkälä et al performed a randomized controlled trial to determine the effects of exercise in 210 home-dwelling patients with Alzheimer disease, including effects on both physical functioning and the use and costs of health and social services for patients and spousal caregivers. See the invited commentary by Clarfield and Dwolatzky.
Feldman et al determined whether they could decrease the number of laboratory tests ordered in a tertiary care hospital by presenting providers with test fees at the time of order entry. See the invited commentary by Tierney.
Dong and Simon examine the relationship between overall elder abuse and specific subtypes of elder abuse and rate of hospitalization in a communitydwelling population of older adults. Monod provides an Invited Commentary, and Covinsky, an Editor’s Note.
Borne and coauthors review implantable cardioverter-defibrillator therapies, their effects on health outcomes, and current methods to reduce these therapies.